AJR ARRS Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henn, A. R.
Right arrow Articles by Zagoria, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henn, A. R.
Right arrow Articles by Zagoria, R. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
AJR 2003; 181:1005-1010
© American Roentgen Ray Society

Original Report

Percutaneous Radiofrequency Ablation of Hepatic Metastases for Symptomatic Relief of Neuroendocrine Syndromes

Adam R. Henn1, Edward A. Levine2, William McNulty3 and Ronald J. Zagoria1

1 Department of Radiology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1088.
2 Department of Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1088.
3 Hanover Medical Specialists, 1520 Physicians Dr., Wilmington, NC 28401.

OBJECTIVE. The purpose of this study was to evaluate the efficacy of percutaneous radiofrequency ablation of hepatic neuroendocrine metastases for symptomatic relief of neuroendocrine syndromes.

CONCLUSION. Percutaneous radiofrequency ablation, a minimally invasive technique, is an effective and safe way to reduce systemic symptoms in patients with hepatic metastases from neuroendocrine neoplasms.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
L. B. J. van Iersel, E. J. Hoekman, H. Gelderblom, A. L. Vahrmeijer, E. L. van Persijn van Meerten, F. G. J. Tijl, H. H. Hartgrink, P. J. K. Kuppen, J. W. R. Nortier, R. A. E. M. Tollenaar, et al.
Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
Ann. Surg. Oncol., July 1, 2008; 15(7): 1891 - 1898.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
M. J. Steward, V. S. Warbey, A. Malhotra, M. E. Caplin, J. R. Buscombe, and D. Yu
Neuroendocrine Tumors: Role of Interventional Radiology in Therapy
RadioGraphics, July 1, 2008; 28(4): 1131 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
D. W. Barker, R. J. Zagoria, K. A. Morton, P. V. Kavanagh, and P. Shen
Evaluation of Liver Metastases After Radiofrequency Ablation: Utility of 18F-FDG PET and PET/CT
Am. J. Roentgenol., April 1, 2005; 184(4): 1096 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
A R Gillams
Liver ablation therapy
Br. J. Radiol., September 1, 2004; 77(921): 713 - 723.
[Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
R. S. Shapiro, R. J. Zagoria, E. A. Levine, and A. R. Henn
Cryotherapy and Percutaneous Ablation
Am. J. Roentgenol., June 1, 2004; 182(6): 1597 - 1597.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Roentgen Ray Society.